AEGR

Aegerion Pharmaceuticals Inc

A biopharmaceutical company founded in 2005 that developed treatments for rare genetic diseases. Its drug Juxtapid (lomitapide) treats a rare hereditary condition causing extremely high cholesterol, while Myalept (metreleptin) addresses complications of fat-tissue disorders. Its name echoes the Latin root for "sick," fitting a firm built around rare illness; in 2016 it merged with Canada's QLT to form Novelion Therapeutics.

No 8-K or 6-K filings recorded.